Chest
Systemic Sclerosis-Associated Interstitial Lung Disease: What We Know and How to Incorporate Guidelines into Clinical Practice.
Anthony J Esposito, Kavitha C Selvan, Carrie Richardson, Dinesh Khanna, Bradford C Bemiss, Elana J Bernstein, Jonathan H Chung, Christian W Cox, Jane E Dematte, Christopher P Denton, Oliver Distler, Monique E Hinchcliff, Vanessa Smith, Mary E Strek, John Varga
Published: 202510.1016/j.chest.2025.11.047
Abstract
TOPIC IMPORTANCE: Interstitial lung disease (ILD) affects 40-60% of patients with systemic sclerosis (SSc) and represents the leading cause of death. While treatment options for SSc-ILD remain limited, randomized controlled trials (RCTs) have demonst…
Preview only. Read the full abstract at the source